Northern Trust Corp Raises Position in MediWound Ltd. (NASDAQ:MDWD)

Northern Trust Corp increased its holdings in MediWound Ltd. (NASDAQ:MDWD - Free Report) by 94.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 144,768 shares of the biopharmaceutical company's stock after acquiring an additional 70,367 shares during the period. Northern Trust Corp owned about 1.34% of MediWound worth $2,577,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of MDWD. Rhumbline Advisers lifted its stake in MediWound by 7.3% in the fourth quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company's stock valued at $193,000 after purchasing an additional 739 shares during the last quarter. Barclays PLC lifted its stake in MediWound by 11.2% in the fourth quarter. Barclays PLC now owns 12,412 shares of the biopharmaceutical company's stock valued at $221,000 after purchasing an additional 1,249 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in MediWound by 154.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 1,162 shares during the last quarter. Geode Capital Management LLC lifted its stake in MediWound by 3.6% in the fourth quarter. Geode Capital Management LLC now owns 98,710 shares of the biopharmaceutical company's stock valued at $1,757,000 after purchasing an additional 3,408 shares during the last quarter. Finally, Essex Investment Management Co. LLC lifted its stake in MediWound by 30.7% in the fourth quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company's stock valued at $2,651,000 after purchasing an additional 35,012 shares during the last quarter. 46.83% of the stock is owned by institutional investors.

MediWound Price Performance

Shares of NASDAQ:MDWD traded up $0.26 during trading on Thursday, hitting $21.34. 46,524 shares of the company were exchanged, compared to its average volume of 91,022. The company has a market cap of $230.64 million, a PE ratio of -7.36 and a beta of 0.30. The stock has a 50 day moving average of $17.78 and a 200 day moving average of $17.73. MediWound Ltd. has a 52-week low of $12.78 and a 52-week high of $24.00.

MediWound (NASDAQ:MDWD - Get Free Report) last posted its earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.58. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. The firm had revenue of $3.96 million for the quarter, compared to the consensus estimate of $5.20 million. During the same quarter in the prior year, the business posted ($1.05) earnings per share. Sell-side analysts forecast that MediWound Ltd. will post -2.66 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MDWD has been the topic of several research analyst reports. HC Wainwright set a $31.00 price objective on MediWound and gave the company a "buy" rating in a research note on Thursday, May 22nd. Wall Street Zen upgraded MediWound to a "sell" rating in a research note on Friday, March 21st. Craig Hallum assumed coverage on MediWound in a research report on Friday, February 28th. They set a "buy" rating and a $39.00 target price on the stock. Finally, Alliance Global Partners assumed coverage on MediWound in a research report on Friday, May 2nd. They set a "buy" rating and a $25.00 target price on the stock. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $31.25.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.